Duolingo's rollercoaster week highlights a crucial risk factor to companies: Chart of the Week
Something that the language-learning platform Duolingo learned this week, on the receiving end of that novel dynamic.
After the company posted a fantastic quarter, fueling a 30% stock surge, a stroke of bad luck saw it get jolted.
It just so happened that OpenAI debuted its latest model, GPT-5, which demonstrated, among many other things, its ability to create a language-learning tool from a short prompt.
OpenAI researcher Yann Dubois asked the model to create an app to help his partner learn French. And in a few minutes GTP-5 churned out several iterations, with flashcards, a progress tracker, and even a simple snake-style game with a French twist, a mouse and cheese variation to learn new vocab.
Sign up for the Yahoo Finance Morning Brief
By subscribing, you are agreeing to Yahoo's
Terms
and
Privacy Policy
The GPT-5 debut instantly wiped out a big chunk of Duolingo's gains, cutting the 30% gains in half. But the downward momentum continued Friday, with the stock sinking 4% to end the week.
C'est la vie.
The company's corporate lawyers, of course, did warn against this in its annual 10-K, albeit in boilerplate language. Tucked into the risk factors section, Duolingo notes, "It is possible that a new product could gain rapid scale at the expense of existing brands through harnessing a new technology (such as generative AI)."
Consider this another warning to anyone making software.
There's also irony in the wild swings. Part of Duolingo's successful quarter stemmed from the business's efficient use of AI. Gross margins, the company said, outperformed management expectations due to lower AI costs. And AI conversational features have become part of the company's learning tools, helping achieve double-digit subscriber growth. Earlier this year, CEO Luis von Ahn shared a memo on LinkedIn outlining his vision to make Duolingo an "AI-first" company.
But the enthusiasm for AI, which led to the initial stock bump this week, also led to the clawback. AI giveth and taketh away.
Duolingo's roller-coaster ride highlights the risks of competing in the space. Rapid development and fierce competition can leave firms suddenly behind — perceived as under threat, inferior, or obsolete —from every iteration of OpenAI's models and from the moves of other influential AI players vying to transform computing and productivity.
OpenAI's new flagship technology arrives more than two years after the release of GPT-4. But the onset of software on demand, of allowing people to conjure up apps using a few words and without any coding know-how, underscores why AI hardware companies are also such a hot play on Wall Street.
Firms building out AI infrastructure are seen as even more desirable than cheaper-to-invest-in software companies. You can't just vibe code the construction of a data center.
But to be fair to Duolingo, and to my mother-in-law, a high school French teacher, you can't exactly do that with language learning either.
Hamza Shaban is a reporter for Yahoo Finance covering markets and the economy. Follow Hamza on X @hshaban.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 minutes ago
- Yahoo
Hims & Hers Shares Plunge. Is This a Buying Opportunity or Should Investors Run for the Hills?
Key Points Hims & Hers Health continues to post robust growth. Shares sold off, however, after revenue missed analyst expectations. The stock is still reasonably valued given its growth prospects. 10 stocks we like better than Hims & Hers Health › Hims & Hers Health (NYSE: HIMS) is one of the most volatile stocks on the market at the moment, prone to big swings in either direction. This is true even intraday, as the stock plunged following the company's second-quarter results, only to rally back, only to plunge again. As of this writing, the stock is still trading up more than 130% this year. Let's take a closer look at the most recent earnings results for this telehealth company focused on providing accessible and affordable healthcare solutions for various health and wellness needs, and its prospects. Who knows, you might want to jump in on this somewhat volatile growth stock. Hims saw strong revenue growth in Q2 Hims & Hers continued to deliver outstanding revenue growth in Q2, with sales climbing 73% year over year to $544.8 million. That was toward the high end of its forecast for revenue of $530 million to $550 million, but it missed analyst expectations for revenue of $552 million. Monthly online revenue per subscriber jumped 30% to $74 per month, while the number of subscribers climbed 31% to nearly 2.44 million. The company said that the number of subscribers in both oral weight loss and dermatology grew more than 55% in the quarter. Customers using at least one personalized subscription increased by 89% to 1.5 million, representing more than 60% of the Hims & Hers subscriber base. It said that 70% of new patients who join the platform use a personalized treatment plan, and that the number of subscribers using a personalized treatment plan to treat multiple conditions skyrocketed 170% to more than 500,000. Revenue from GLP-1 weight loss drugs fell from $230 million in Q1 to $190 million in Q2, after Novo Nordisk ended a partnership with the telehealth company. Nonetheless, it still expects to generate $725 million of revenue this year from weight loss drugs, led by oral weight loss products and personalized doses. Hims & Hers continues to spend heavily on marketing to attract new customers. During the quarter, its marketing spending jumped 50% to nearly $218 million. Marketing expenses took up 40% of revenue in the quarter, though that was down from 46% a year ago, so the company continues to see leverage in this area despite the increased spending. Adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) surged to $82.2 million from $39.3 million a year ago. Adjusted earnings per share (EPS) came in at $0.17, topping the $0.15 analyst consensus as compiled by LSEG. Metric Q1 Results Growth (YOY) Revenue $544.8 million 73% Monthly online revenue per subscriber $74 30% Subscribers 2.44 million 31% Adjusted EBITDA $82.2 million 109% Adjusted EPS $0.17 183% Marketing expense $231 million 77% Marketing as % of revenue 40% (600 basis points) Gross margin 76% (500 basis points) Data source: Hims & Hers Health. YOY = year over year. Looking ahead, Hims & Hers maintained its forecast for 2025 revenue to be between $2.3 billion and $2.4 billion, equal to growth of 56% to 63%. It also kept its adjusted EBITDA guidance of $295 million to $335 million. For Q3, it projected revenue of between $570 million and $590 million, and adjusted EBITDA of $60 million to $70 million. The company is starting to look toward international expansion to bolster growth. It will begin by focusing on Canada next year, while its acquisition of Zava in July will help it expand into Europe. It also anticipates entering the Latin American and Asian markets in the coming years. Hims & Hers also continues to expand into new areas. It will launch hormonal health soon, starting with lab testing. The company believes this will help it reach its targets of $6.5 billion in revenue and $1.3 billion in adjusted EBITDA in 2030. Is the stock a buy? Hims & Hers continues to be a growth engine. Even though there's been some disruption from its spat with Novo Nordisk, it is still seeing strong growth across different health categories. With the company moving into new areas, like hormonal health and longevity, and looking to expand internationally, it has a lot of growth opportunities ahead. Meanwhile, with the majority of its subscribers on personalized treatment plans, it has a pretty sticky user base. From a valuation standpoint, the stock trades at a forward price-to-earnings (P/E) ratio of around 55 based on the analyst consensus for 2025. But its forward price/earnings-to-growth ratio (PEG) is under 0.6, and stocks with PEG ratios below 1 are usually considered undervalued. Given that it operates a subscription business with high gross margins, you can also look at the stock from a price-to-sales perspective; on that front, it trades at a multiple of 5.5 times 2025 analyst estimates. Overall, I'd say, based on the type of business the company is in, that it's still reasonably priced. However, it's still a volatile stock that carries some risk depending on what happens in the weight loss segment. Still, I really like its international opportunity, and think Hims & Hers Health could have solid long-term upside from here. Should you invest $1,000 in Hims & Hers Health right now? Before you buy stock in Hims & Hers Health, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Hims & Hers Health wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,427!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,119,863!* Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025 Geoffrey Seiler has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Hims & Hers Health. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. Hims & Hers Shares Plunge. Is This a Buying Opportunity or Should Investors Run for the Hills? was originally published by The Motley Fool 登入存取你的投資組合
Yahoo
5 minutes ago
- Yahoo
If You'd Invested $1,000 in Palantir Stock 3 Years Ago, Here's How Much You'd Have Today
Key Points Palantir's AIP contributed to accelerated revenue growth. Its growth has led to a pricey valuation, making its near-term direction less certain. 10 stocks we like better than Palantir Technologies › Palantir Technologies (NASDAQ: PLTR) stock has been on a tear since last year's U.S. presidential election. Since the election on Nov. 5, the stock is up by about 250%. While that is a considerable return, it is relatively modest compared to how the stock has performed over the last three years, when the market and Palantir were in the middle of a bear market. Amid the rising popularity of AI and its productivity solution, Palantir's returns since that time are nothing short of eye-popping. Palantir over the last three years If one had bought Palantir on Aug. 8, 2022, a $1,000 investment would be worth about $15,700 today. Three years ago, a dramatic pullback from the highs of the 2021 bull market left Palantir trading below $10 per share, the approximate level where it sold on its first day of trading on Sept. 30, 2020. Additionally, it got off to a slow start as it briefly fell below $6 per share in December 2022. Nonetheless, Palantir began moving higher in 2023, particularly after Open AI's release of an upgraded version of ChatGPT put the spotlight on generative AI. Palantir responded with its own generative AI solution, the artificial intelligence platform (AIP), in April 2023. Customers began reporting massive productivity gains. Over time, the stock's growth accelerated as revenue growth began to rise at a significantly faster rate. Consequently, the stock reached stratospheric highs, with a P/E ratio approaching 600. Although such earnings multiples can be common with growth stocks, its price-to-sales (P/S) ratio of 130 all but verifies that the market has priced the stock for perfection. That increases the odds of a dramatic fall at the slightest hint of bad news. However, few can deny the success of Palantir's investors over the last three years. Even if its near-term prospects are less clear, Palantir should succeed long term, since its tools have delivered massive productivity gains for its customers. Should you invest $1,000 in Palantir Technologies right now? Before you buy stock in Palantir Technologies, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Palantir Technologies wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,427!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,119,863!* Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025 Will Healy has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Palantir Technologies. The Motley Fool has a disclosure policy. If You'd Invested $1,000 in Palantir Stock 3 Years Ago, Here's How Much You'd Have Today was originally published by The Motley Fool
Yahoo
12 minutes ago
- Yahoo
Tourism and tech support Scotland's economic growth
Scotland's economy continues to show signs of improvement as it enters the second half of 2025 – with increasing confidence across mid-market businesses, solid performances across technology, media and telecommunications companies, and the fastest uptick in business services activity since 2024. The latest Royal Bank of Scotland report, which includes new data on the country's small and mid-market sectors, shows that the nation has remained on a positive growth trajectory since May. Scottish employment, led by the services sector, grew in May and has remained broadly stable through the first half of the year, comparing favourably against the rest of the UK. READ MORE: Oasis bring supersonic boost to Scottish economy READ MORE: Kate Forbes' resignation is a cautionary tale for all employers While concerns around rising employment costs and potential negative consequences for the tourism sector persist, the industry continues to help drive activity across all regions of Scotland. After a strong June, confidence that opportunities for growth will continue into next year are at their highest this year, with five of the six areas of the Scottish private sector economy tracked by the survey expecting further improvement. Across the private sector as a whole, a third of firms predict a rise in output in the next 12 months, with one in 10 forecasting a reduction. The manufacturing sector is still facing considerable challenges, with production in Scotland remaining in contraction in June – though this was at a slower pace than seen in May, with consumer goods showing more resilience than other parts of the sector towards the end of the first half. Paul Thwaite, chief executive of NatWest Group, said: 'While we continue to see a mixed picture for businesses in Scotland, it is encouraging to see some signs of momentum across the economy. 'Firms remain resilient, with activity and confidence improving in many areas, although this varies by sector as well as individual circumstances.' RBS' chief economist Sebastian Burnside said: 'Following the challenging start to the year, Scotland's economy hit a high point in June with private sector businesses reporting their strongest growth of the year so far. 'Business services and travel and tourism led the way, with mid-market firms showing renewed confidence in future growth. 'Scotland's businesses report higher employment trends than other parts of the UK, with mid-market services businesses and technology, media and telecoms firms scoring especially highly. 'Whilst there has been some stabilisation, businesses are still facing a rapidly changing international environment and domestic pressures — as we can see with manufacturers who reported tougher business conditions in June, particularly amongst smaller firms.' Don't miss the latest headlines with our twice-daily newsletter - sign up here for free. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
